BH3 Mimetics May Have Utility in T Cell Non-Hodgkin LymphomasT cell non-Hodgkin lymphomas (T-NHL) are a heterogeneous group of diseases. Most of the treatments used for T-NHL are extrapolated from the treatment of B cell lymphomas and do not take into account any unique biology of T-NHL. A handful of agents are FDA-approved for relapsed and refractory T-NHL, but these agents have response rates on the order of 20-30%. Thus, there is a need for effective, rational therapies in T-NHL. (Source: Clinical Lymphoma, Myeloma and Leukemia)Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Elizabeth Brem, Raphael Koch, Rachael Clark, Thomas Kupper, David Weinstock, Anthony Letai Source Type: research

Analysis Of CD30 Expression in Patients With Diffuse Large B-Cell Lymphoma Treated at a Brazilian Universtiy HospitalDiffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and includes a heterogeneous group of diseases, identified by their morphological, immunohistochemistry (IHC) and molecular aspects. The expression of the CD30 by IHC has been described as having a good prognosis and correlated with an increase in progression-free survival(PFS) and overall survival(OS). (Source: Clinical Lymphoma, Myeloma and Leukemia)Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Bruno Francisco Buzetti Spinelli, Caroline Bonamin dos Santos Sola, Melyssa Grignet Ribeiro, Ana Paula Percicote, Samir Kanaan Nabhan Source Type: research

The Role of FLI1 in mRNA Splicing and rRNA Processing of Diffuse Large B Cell Lymphoma (DLBCL)DLBCL is the commonest lymphoma, accounting for 30-40% of the cases, and a clinically aggressive lymphoma. A large portion of DLBCL patients can nowadays be cured with chemotherapeutic regimens, such as R-CHOP. However, approximately 30-40% of patients will present a refractory disease or will experience a relapse, indicating the need of better understanding the disorder for further therapeutic improvements. Our group has functionally characterized an 11q24.3 region that is recurrently gained in DLBCL determining an upregulation of the transcriptional factor FLI1 that occurs in up to 25% of patients (Bonetti, Testoni et al...Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Giulio Sartori, Sara Napoli, Luciano Cascione, Valdemar Priebe, Andrea Rinaldi, Francesco Bertoni Source Type: research

Myeloid Differentiation Factor 88 (MYD88) Gene Mutation in Diffuse Large B-Cell Lymphomas: Should it be Included in Routine?Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in adults, accounting for 35% –40% of all cases. NF-κB constitutive activation is the most important alteration found in ABC DLBCL. Some genes are inactivated by somatic mutations and deletions such as TNFAIP3 (30% of cases), others, such as CARD11 (10% of cases), CD79B and CD79A (∼20% of cases), and MYD88 L265P (6-30% of c ases) are activated mostly by somatic mutations. MYD88 mutations are usually described in DLCBL ABC subtype and extranodal disease. (Source: Clinical Lymphoma, Myeloma and Leukemia)Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Laura Fogliatto, Marines Barra, Yuri Strey, Paula Oliveira, Israel Bendit, Camila Bender, Kamila Grokoski, Tito Costa, Andrea Kramer, Claudia Bica Source Type: research

Availability of Essential Medicines for Pediatric Oncology in ArmeniaDuring recent decades substantial improvements has been documented in pediatric oncology and currently in high-income countries the survival of pediatric cancer is around 85%, however, the picture is totally different in low and middle income countries (LMIC), where around 80% of all pediatric cancer cases are documented: in LMIC pediatric cancer survival can range from 0 up to 50-60%. Among the others, one of the main challenges in LMIC is the availability of cancer medications. (Source: Clinical Lymphoma, Myeloma and Leukemia)Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Tamara Simonyan, Ruzanna Papyan, Lilit Sargsyan, Lusine Hakobyan, Varduhi Grigoryan, Hakob Topchyan, Arpina Azaryan, Armen Tananyan, Gevorg Tamamyan Source Type: research

Ruxolitinib for Steroid-Refractory GVHDSteroid-refractory GVHD (SR-GVHD) is associated with poor outcomes and high rates of morbidity and mortality, and second-line agents have failed to demonstrate significant efficacy. A novel JAK1/2 inhibitor, ruxolitinib, which has been approved for subsets of myelofibrosis and polycythemia vera, has emerged as a possible therapeutic option in patients with SR-GVHD. (Source: Clinical Lymphoma, Myeloma and Leukemia)Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Alexander Coltoff, Guido Lancman, Amir Steinberg Source Type: research

Distribution Chemotherapy Response Modulating Genetic Polymorphisms in Armenian PopulationPrimary chemotherapy drug resistance is a one of the major issues of medical hematology-oncology affecting about 20% of all patients. In Armenia, clinical data suggest that the rate of primary resistance depends on the disease and treatment type and varies in the range of 10-30%. One of the mechanisms of resistance is a drug inactivation mediated by metabolizing enzymes and it has been known that the variability of those genes contributes to the response to drugs and treatment efficacy. In Armenia a number of drugs are used for treatment acute and chronic hematology-oncological diseases, such as doxorubicin and vincristine...Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Arsen Arakelyan, Yervand Hakobyan, Ani Melkonyan Source Type: research